Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim

Generated: March 24, 2019

DrugPatentWatch Database Preview

Litigation Details for AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

« Back to Dashboard

AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

Docket ➤ Try a Free Trial Date Filed 2016-01-26
Court District Court, N.D. California Date Terminated 2016-07-22
Cause 15:1 Antitrust Litigation Assigned To William Haskell Alsup
Jury Demand Plaintiff Referred To
Patents 5,814,639; 5,914,331; 6,642,245; 6,703,396; 7,176,220; 7,390,791; 7,635,704; 7,800,788; 7,803,788; 8,148,374; 8,633,219; 8,754,065; 8,981,103
Attorneys Arti L Bhimani; Bruce C Haas; Charles Lagrange Coleman , III; Christopher E Loh; Daniel Paul Hipskind; David Lloyd Anderson; Dorian Seawind Berger; Gary N. Frischling; Geoffrey M. Ezgar; Jason George Sheasby; Jeffrey Scott Cashdan; Jerome W Hoffman; John Preston Long; Jordan Engelhardt; Keith Andrew Orso; Liza Michalina Brereton; Matthew H Dawson; Neal N. Beaton; Ryan M. Sandrock; Thomas Andrew Myers; Timothy Tully Scott; William Francis Cavanaugh; Yite John Lu
Firms Aids Healthcare Foundation; Berger and Hipskind LLP; Fitzpatrick, Cella, Harper & Scinto; Holland & Knight LLP; Holland and Knight, LLP; Irell & Manella LLP; King & Spalding LLP; King and Spalding LLP; Patterson Belknap Webb & Tyler LLP; Sidley Austin LLP
Link to Docket External link to docket
Small Molecule Drugs cited in AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc.

Details for AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-01-26 1 No. 5,814,639, entitled “Method for the synthesis, compositions and use of…years before Gilead obtained a patent on TAF, Gilead 11 had patented a similar prodrug called Tenofovir…weakness of the patents covering TAF, Gilead illegally seeks to 13 extend the period of patent exclusivity… The patents on TDF expire in 2017 and 2018. The impending expiration of the 23 TDF patents presented…was heavily reliant on the patent 24 exclusivity period of the TDF patents to prevent entry by generic External link to document
2016-07-06 108 12 7,390,791 — “Prodrugs of phosphonate nucleotide Gilead … 9 patents (regardless of the patent owner) that it believes cover the … until the patent expires (if it has not already expired) or by stating that the patent is invalid or… constitutes an artificial act of patent infringement. If the patent owner initiates … PATENT PATENT OWNER External link to document
2016-03-21 34 any of the patents identified in Count 1 of the Complaint including U.S. Patent No. 8,633,219.3 1n sum,…not JTI USA_as the owner of U.S. Patent No. 8,633,219 (the “‘219 Patent”). Nowhere is J T1 USA_identified…embodies a patent exhausts the patent holder’s rights and prevents the patent holder from invoking patent law…Exhibit C at p. 1. The official patent, obtained from the United States Patent and Trademark Office, clearly…alleged) that it has any. ‘219 Patent. The remaining patents set forth in the Complaint are alleged External link to document
2016-03-21 35 B - Gilead Form 10-K, # 3 Exhibit C - U.S. Patent 8,633,219)(Related document(s) 34 ) (Hoffman, Jerome External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.